A Phase 2, Multicenter, Randomized, Double-Masked, Vehicle- Controlled, 6-Week Clinical Study to Assess the Dose Regimen, Safety and Efficacy of BRM421 Ophthalmic Solution in Patients With Dry Eye Disease
Latest Information Update: 12 Aug 2025
At a glance
- Drugs BRM 421 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors BRIM Biotechnology
Most Recent Events
- 30 Jul 2025 New trial record